CTLA4 and cancer: Novel immune treatments for oncology, such as mAbs, aiming at CTLA-4 and the PD-1/PD-L1 axis, exemplify the advances in innovative cancer immunotherapies [4,5,6] and have revolutionized the landscape of cancer therapy.